Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
In a recent transaction, Karen A. Foster, the Chief Quality and Operations Officer at BioLife Solutions Inc. (NASDAQ:BLFS), sold 7,869 shares of the company’s common stock. The sale comes as the stock has experienced a 9% decline over the past week, according to InvestingPro data, though the company maintains a strong financial health rating. The shares were sold at a price of $22.66 each, amounting to a total transaction value of $178,311. Following this sale, Foster holds 195,853 shares in the company.
The transaction was executed under a Rule 10b5-1 trading plan, which was adopted to satisfy tax withholding obligations related to the vesting of restricted stock.
In other recent news, BioLife Solutions reported strong financial results for the fourth quarter of 2024, with revenue reaching $22.7 million, surpassing analyst estimates. The company posted a net loss of $2.0 million, which was smaller than projected. BioLife’s Cell Processing segment achieved a 37% year-over-year revenue increase to $20.3 million, marking its fifth consecutive quarter of growth. Analysts at H.C. Wainwright and Benchmark responded positively, raising their price targets to $30 while maintaining a "Buy" rating, citing the company’s robust performance and optimistic guidance for 2025. BioLife anticipates total revenue for 2025 to be between $95.5 million and $99 million, reflecting a 16-20% growth over 2024. The company also expects Cell Processing revenue to grow 18-21% in the coming year. KeyBanc Capital Markets maintained an Overweight rating with a $33 target, emphasizing BioLife’s potential to amplify revenue through new product introductions and the Sexton portfolio. BioLife’s biopreservation media is now incorporated into 17 approved cell and gene therapies, with potential for further approvals and expansions. These developments highlight BioLife’s strengthened market position following strategic asset sales to focus on its core business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.